Gsk (GLAXF) Notes Payables (2009 - 2026)

Gsk's Notes Payables history runs 18 years deep, the most recent figure standing at -$6.8 billion for Q1 2026.

• In Q1 2026, Notes Payables fell 2434.8% year-over-year to -$6.8 billion; the TTM figure through Mar 2026 stood at -$6.8 billion (down 2434.8% YoY), while the FY2025 annual figure was -$4.0 billion, down 232.26% from the prior year.
• Notes Payables was -$6.8 billion for Q1 2026 at Gsk, down from -$4.0 billion in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $4.6 billion in Q4 2022 to a low of -$7.4 billion in Q2 2023.
• Historically, Notes Payables has averaged -$1.4 billion across 5 years, with a median of -$289.8 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Notes Payables soared 93.96% in 2023, then slumped 2434.8% in 2026.
• A 5-year view of Notes Payables shows it stood at $4.6 billion in 2022, then slipped by 24.68% to $3.5 billion in 2023, then fell by 13.65% to $3.0 billion in 2024, then slumped by 232.89% to -$4.0 billion in 2025, then slumped by 69.73% to -$6.8 billion in 2026.
• The last three Notes Payables figures came in at -$6.8 billion (Q1 2026), -$4.0 billion (Q4 2025), and -$724.6 million (Q3 2025), per Business Quant data.